Zobrazeno 1 - 10
of 96
pro vyhledávání: '"L. Boggio"'
Autor:
Gianluca Tavoletti, Gianluca Avallone, Carlo A. Maronese, Francesca L. Boggio, Angelo V. Marzano, Gianluca Nazzaro
Publikováno v:
Australasian Journal of Dermatology. 64
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Carlo A. Maronese, Andrea Beretta, Gianluca Avallone, Francesca L. Boggio, Dario A. Marletta, Giulia Murgia, Marco Cusini, Andrea Gori, Carlo G. Carrera, Alessandra Di Benedetto, Stefano Ramoni, Angelo V. Marzano
Publikováno v:
British Journal of Dermatology. 187:822-823
Publikováno v:
Sexually transmitted infections.
Autor:
Stefanie DiGiandomenico, Pamela A. Christopherson, Sandra L. Haberichter, Thomas C. Abshire, Robert R. Montgomery, Veronica H. Flood, L. Valentino, T. Abshire, A. Dunn, C. Bennett, J. Lusher, M. Rajpurkar, W.K. Hoots, D. Brown, A. Shapiro, J. Di Paola, S. Lentz, J. Gill, C. Leissinger, M. Ragni, J. Hord, M. Manco‐Johnson, A. Ma, L. Boggio, A. Sharathkumar, R. Gruppo, B. Kerlin, J. Journeycake, R. Kulkarni, D Mahoney, L. Mathias, A. Bedros, C. Diamond, A. Neff, A. Paroskie, D. DiMichele, P. Giardina, A. Cohen, M. Paidas, E. Werner, A. Matsunaga, T. Singer, M. Tarantino, J. Roberts, F. Shafer, B. Konkle, A. Cuker, P. Kouides, D. Stein, D. Lillicrap, P. James
Publikováno v:
J Thromb Haemost
Essentials Patients with von Willebrand disease were enrolled in our study. Type 2 VWD diagnoses were based on original test results. Repeat evaluation resulted in many patients receiving a different type 2 diagnosis. Some genetic variants were parti
Autor:
Pamela A. Christopherson, Sandra L. Haberichter, Veronica H. Flood, Crystal L. Perry, Brooke E. Sadler, Daniel B. Bellissimo, Jorge Di Paola, Robert R. Montgomery, T Abshire, H Weiler, D Lillicrap, P James, J O’Donnell, C Ng, C Bennett, R Sidonio, M Manco‐Johnson, J Journeycake, A Zia, J Lusher, M Rajpurkar, A Shapiro, S Lentz, J Gill, C Leissinger, M Ragni, M Tarantino, J Roberts, J Hord, J Strouse, A Ma, L Valentino, L Boggio, A Sharathkumar, R Gruppo, B Kerlin, R Kulkarni, D Green, K Hoots, D Brown, D Mahoney, L Mathias, A Bedros, C Diamond, A Neff, D DiMichele, P Giardina, A Cohen, M Paidas, E Werner, A Matsunaga, F Shafer, B Konkle, A Cuker, P Kouides, D Stein
Publikováno v:
Journal of thrombosis and haemostasis : JTHREFERENCES. 20(7)
Type 3 von Willebrand Disease (VWD) is a rare and severe form of VWD characterized by the absence of von Willebrand factor (VWF).As part of the Zimmerman Program, we sought to explore the molecular pathogenesis, correlate bleeding phenotype and sever
Autor:
Carlo A Maronese, Francesca L Boggio, Francesco Barberi, Maurizio Romagnuolo, Davide Riva, Serena Giacalone, Angelo Cattaneo, Marco Cusini, Angelo V Marzano
Publikováno v:
The Australasian journal of dermatology. 63(2)
Autor:
Francesca L, Boggio, Elena, Guanziroli, Marco, Barella, Luigia, Venegoni, Emilio, Berti, Stefano, Ferrero, Antonella, Coggi, Raffaele, Gianotti, Alessandro, Del Gobbo
Publikováno v:
Italian Journal of Dermatology and Venereology. 156
Clear cell morphology has been described in several cutaneous neoplasms either as a specific feature of some entities either as a morphological variant in the spectrum, and these two entities are frequently considered together in the differential dia
Autor:
R.A. Gruppo, D. Malan, J. Kapocsi, L. Nemes, C.R.M. Hay, L. Boggio, P. Chowdary, G. Tagariello, A. von Drygalski, F. Hua, M. Scaramozza, S. Arkin, C.R.J.R. Hermans, C. Claes, I. Hanes, I. Huyghe, C. Kantaridis, L.M. da Costa, M.‐N. Ndongo, W. Petit, E.M. Santagostino, A. Cannavo, M.R. Fasulo, M.E. Mancuso, A. Tosetto, G. Castaman, L. Candiotto, P. Radossi, E. Scarpa, M.P. Smith, A.E. Dick, R.A. Robson, D.S. Waaka, C.J. Wynne, Z.E. Punt, K.R. Kavakli, C. Balkan, M. Duyu, S. Goksel, B. Karapinar, A.R. Ozyurek, G. Saydam, D.Y. Karapinar, M. Laffan, C.M. Millar, P.I. Suppiah, C.K. Rizleigh, G.P. Chowdary, J.S. Davies, E.L. Fosbury, S. Gill, G.N. Pike, J. Varghese Thachil, M. Recht, J. Deutsche, J. Taylor, K.A. Kalinyak, E.S. Mullins, J.S. Palumbo, C.T. Quinn, C. Tarango, S. Tarabar, P.A. Chandler, L. Deats, S.R. Deshpande, N.U. Epstein, A.G. Hansson, S.S. Pawlak, D. Rudin, L.A.J. Valentino, N.C. Kakodkar, M.L. Simpson, P.F. Fogarty, Tami L. Bach, Elaine Y. Chiang, J.W. Adamson, C.S. Glass, N. Sidhu, T.D. Tucker‐Greene
Publikováno v:
Journal of Thrombosis and Haemostasis. 16:1984-1993
Essentials Marzeptacog alfa (activated) [MarzAA] is a novel variant of activated human factor VII. A phase 1 dose escalation trial of MarzAA was conducted in subjects with severe hemophilia. MarzAA was safe and tolerated at intravenous doses up to 30
Publikováno v:
Value in Health. 18(7)